# Ecovyst Inc.: overview

ECVT · NYSE · CIK 1708035 · [Materials](/sectors/materials.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/ecvt.md) · [Financials](/companies/ecvt/financials.md) · [Filings](/companies/ecvt/filings.md) · [Insiders](/companies/ecvt/insiders.md)

Latest reported revenue: [$250.0m](/filings/0001708035-26-000090.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 6, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001708035-26-000090).

## Last eight quarters

| Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [154](/filings/0001708035-26-000053.md) | [149](/filings/0001708035-26-000053.md) | [143](/filings/0001708035-26-000067.md) | [176](/filings/0001708035-26-000090.md) | [205](/filings/0001708035-26-000053.md) | [199](/filings/0001708035-26-000053.md) | [215](/filings/0001708035-26-000067.md) | [250](/filings/0001708035-26-000090.md) |
| Gross margin | % | [29.3%](/filings/0001708035-26-000053.md) | [28.9%](/filings/0001708035-26-000053.md) | [13.3%](/filings/0001708035-26-000067.md) | [22.8%](/filings/0001708035-26-000090.md) | [25.4%](/filings/0001708035-26-000053.md) | [23.4%](/filings/0001708035-26-000053.md) | [16.9%](/filings/0001708035-26-000067.md) | [19.9%](/filings/0001708035-26-000090.md) |
| Operating margin | % | [17.9%](/filings/0001708035-26-000053.md) | [15.1%](/filings/0001708035-26-000053.md) | [(0.7%)](/filings/0001708035-26-000067.md) | [9.0%](/filings/0001708035-26-000090.md) | [13.8%](/filings/0001708035-26-000053.md) | [10.9%](/filings/0001708035-26-000053.md) | [5.8%](/filings/0001708035-26-000067.md) | [7.7%](/filings/0001708035-26-000090.md) |
| Net margin | % | [9.3%](/filings/0001708035-26-000053.md) | [(20.4%)](/filings/0001708035-26-000053.md) | [(2.5%)](/filings/0001708035-26-000090.md) | [3.4%](/filings/0001708035-26-000090.md) | [(38.7%)](/filings/0001708035-26-000053.md) | [2.9%](/filings/0001708035-26-000053.md) | [2.0%](/filings/0001708035-26-000090.md) | [3.1%](/filings/0001708035-26-000090.md) |
| Diluted EPS | $ per share | [0.12](/filings/0001708035-26-000053.md) | [(0.26)](/filings/0001708035-26-000053.md) | [(0.03)](/filings/0001708035-26-000067.md) | [0.05](/filings/0001708035-26-000090.md) | [(0.69)](/filings/0001708035-26-000053.md) | [0.05](/filings/0001708035-26-000053.md) | [0.04](/filings/0001708035-26-000067.md) | [0.07](/filings/0001708035-26-000090.md) |
| Free cash flow | $m | [53.6 d](/filings/0001708035-25-000118.md) | [30.9 d](/filings/0001708035-26-000053.md) | [(6.8)](/filings/0001708035-26-000067.md) | [11.0 d](/filings/0001708035-26-000090.md) | [42.8 d](/filings/0001708035-25-000118.md) | [22.9 d](/filings/0001708035-26-000053.md) | [2.8](/filings/0001708035-26-000067.md) | [3.7 d](/filings/0001708035-26-000090.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure.

## Last five fiscal years

| Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [611](/filings/0001708035-24-000070.md) | [820](/filings/0001708035-25-000070.md) | [585](/filings/0001708035-26-000053.md) | [598](/filings/0001708035-26-000053.md) | [724](/filings/0001708035-26-000053.md) |
| Gross margin | % | [28.9%](/filings/0001708035-24-000070.md) | [27.4%](/filings/0001708035-25-000070.md) | [28.5%](/filings/0001708035-26-000053.md) | [27.3%](/filings/0001708035-26-000053.md) | [21.8%](/filings/0001708035-26-000053.md) |
| Operating margin | % | [8.9%](/filings/0001708035-24-000070.md) | [12.7%](/filings/0001708035-25-000070.md) | [15.3%](/filings/0001708035-26-000053.md) | [14.2%](/filings/0001708035-26-000053.md) | [9.0%](/filings/0001708035-26-000053.md) |
| Net margin | % | [(22.9%)](/filings/0001708035-24-000070.md) | [9.0%](/filings/0001708035-25-000070.md) | [12.2%](/filings/0001708035-26-000053.md) | [(1.1%)](/filings/0001708035-26-000053.md) | [(9.8%)](/filings/0001708035-26-000053.md) |
| Diluted EPS | $ per share | [(1.02)](/filings/0001708035-24-000070.md) | [0.55](/filings/0001708035-25-000070.md) | [0.60](/filings/0001708035-26-000053.md) | [(0.06)](/filings/0001708035-26-000053.md) | [(0.61)](/filings/0001708035-26-000053.md) |
| Free cash flow | $m | [69.9](/filings/0001708035-24-000070.md) | [128](/filings/0001708035-25-000070.md) | [78.6](/filings/0001708035-26-000053.md) | [94.3](/filings/0001708035-26-000053.md) | [69.9](/filings/0001708035-26-000053.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/ecvt/insiders.md)

None in coverage.

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $132.8m | 10,666,032 |  | Added +1,931,812 |
| [Rubric Capital Management LP](/funds/1687509.md) | 2026-06-30 | $102.2m | 8,211,888 |  | Reduced −924,179 |
| [DIMENSIONAL FUND ADVISORS LP](/funds/354204.md) | 2026-06-30 | $82.0m | 6,585,047 |  | Added +86,393 |
| [VANGUARD PORTFOLIO MANAGEMENT LLC](/funds/2100121.md) | 2026-06-30 | $75.8m | 6,090,922 |  | Added +846,516 |
| [FMR LLC](/funds/315066.md) | 2026-06-30 | $66.4m | 5,333,701 |  | Added +866,276 |
| [ARROWSTREET CAPITAL, LIMITED PARTNERSHIP](/funds/1164508.md) | 2026-06-30 | $63.9m | 5,132,947 |  | Added +303,913 |
| [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $60.3m | 4,843,861 |  | Reduced −133,719 |
| [BROWN ADVISORY INC](/funds/1345929.md) | 2026-06-30 | $56.4m | 4,533,515 |  | Reduced −308,659 |
| [AMERICAN CENTURY COMPANIES INC](/funds/748054.md) | 2026-06-30 | $43.3m | 3,474,853 |  | Added +1,449,583 |
| [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $39.2m | 3,149,827 |  | Added +386,373 |

## Recent filings

[All 569 filings](/companies/ecvt/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-08-24 | 06:15 ET | [8-K](/filings/0001193125-26-361724.md) | 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-361724 |
| 2026-08-06 | 16:03 ET | [10-Q](/filings/0001708035-26-000090.md) | Quarterly report, period 2026-06-30 | 0001708035-26-000090 |
| 2026-08-05 | 06:00 ET | [8-K](/filings/0001708035-26-000087.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001708035-26-000087 |
| 2026-06-30 | 16:05 ET | [8-K](/filings/0001193125-26-290479.md) | 1.01 Entry into a material agreement; 2.03 New direct financial obligation; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-290479 |
| 2026-05-21 | 16:02 ET | [8-K](/filings/0001708035-26-000070.md) | 5.07 Shareholder vote results | 0001708035-26-000070 |
| 2026-05-05 | 16:00 ET | [10-Q](/filings/0001708035-26-000067.md) | Quarterly report, period 2026-03-31 | 0001708035-26-000067 |
| 2026-05-05 | 06:00 ET | [8-K](/filings/0001708035-26-000063.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001708035-26-000063 |
| 2026-05-04 | 07:44 ET | [8-K](/filings/0001193125-26-202584.md) | 1.01 Entry into a material agreement; 9.01 Financial statements and exhibits | 0001193125-26-202584 |
| 2026-04-15 | 17:16 ET | [DEF 14A](/filings/0001140361-26-014838.md) | Proxy statement, period 2026-05-20 | 0001140361-26-014838 |
| 2026-02-27 | 16:01 ET | [10-K](/filings/0001708035-26-000053.md) | Annual report, period 2025-12-31 | 0001708035-26-000053 |

## Latest annual report

[Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001708035-26-000053.md), filed Feb 27, 2026.

## Forecast league

Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/bc3c6d7f-013e-4a57-9982-0a670c7fa702)

## About the filer

- CIK: 1708035
- Tickers: ECVT
- Exchange: NYSE
- SIC code: 2800 Chemicals & Allied Products
- State of incorporation: DE
- Filer category: Large accelerated filer

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:46 ET. No prices; not investment advice.